Activation of the <scp>EGFR</scp> / <scp>PI3K</scp> / <scp>AKT</scp> pathway limits the efficacy of trametinib treatment in head and neck cancerOfra Novoplansky, Moshe Elkabets|Molecular Oncology|2023Cited by 33
MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancerOfra Novoplansky, Moshe Elkabets|International Journal of Cancer|2019Cited by 31
Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancerOfra Novoplansky, Moshe Elkabets|Journal of Experimental & Clinical Cancer Research|2024Cited by 6